Envista Holdings Corporation announced that it closed the previously disclosed divestiture of its KaVo Treatment Unit & Instrument business. Envista received $317.3 million in cash on the closing date and expects to receive total gross proceeds of $383 million, which includes an earnout and certain adjustments to be paid out by the first half of 2022. Envista will use the proceeds to fund strategic acquisitions and internal investments.
Latest Fintech Insights: IsDBI and IFE Lab Announce Award Winners For Best Application Of Agent-based Simulation In Islamic Finance
Envista Holdings Corporation CEO Amir Aghdaei said, “Envista is focused on its strategic priorities to build and optimize a more consumables and digitally enabled, workflow-oriented portfolio. This divestiture further enables Envista to invest organically and inorganically, expand our product offerings, and realize our purpose of partnering with dental professionals to improve patients’ lives by digitizing, personalizing, and democratizing dental care.”
Browse The Complete News About Fintech : Easebuzz Unveils New Brand Identity Reflecting Company’s Vision of Helping a Million Businesses
The business sold was part of Envista’s Equipment & Consumables segment. Envista’s Imaging business, which also currently uses the KaVo brand for select products, will stay with Envista as part of the Equipment & Consumables segment.
Read More About Fintech News : Northstake to Provide Staking Solutions on Concordium Blockchain
[To share your insights with us, please write to sghosh@martechseries.com]
